Theory Paper IIIDrNB Cardiology – Theory Notes

CARDIAC TRANSPLANTATION

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IINDICATIONS FOR ORTHOTOPIC HEART TRANSPLANTATION (ISHLT 2016/2024 & ESC 2021 CLASS I)

  • End-Stage Heart Failure (Stage D): Advanced systolic, restrictive, hypertrophic, or congenital heart failure with severe refractory symptoms (NYHA Functional Class IIIb to IV or INTERMACS Profiles 1 to 4), recurrent HF hospitalizations, or inotrope/mechanical circulatory support dependency despite optimal Quadruple GDMT, CRT, and structural interventions.
  • Cardiopulmonary Exercise Testing (CPET — Objective Gold Standard):
    • Patients on Beta-Blockers: Peak VO2 of 12 mL/kg/min or less (with maximal effort confirmed by Respiratory Exchange Ratio [RER] greater than 1.05).
    • Patients Intolerant of Beta-Blockers: Peak VO2 of 14 mL/kg/min or less.
    • Young Patients (<50 Years) and Women: Peak VO2 less than 50 percent of predicted.
    • Obese Patients (BMI >=30 kg/m2) or Submaximal Effort (RER <1.05): VE/VCO2 Ventilatory Efficiency Slope greater than 35 (or lean-body-mass-adjusted Peak VO2 <=19 mL/kg/min).
    • Validated Survival Scores: Heart Failure Survival Score (HFSS) in the high/medium-risk range or Seattle Heart Failure Model (SHFM) predicted 1-year survival less than 80 percent.
    • Refractory Ventricular Arrhythmias or Angina: Incessant, life-threatening ventricular arrhythmias (electrical storm) refractory to antiarrhythmic drugs, catheter ablation, and stellate ganglion block, or refractory severe angina not amenable to percutaneous or surgical revascularization.

IIRECIPIENT EVALUATION AND CONTRAINDICATIONS (ISHLT GUIDELINES)

  • Fixed Pulmonary Hypertension (The Crucial Hemodynamic Contraindication):
    • Mechanism: The thin-walled donor right ventricle is conditioned to a normal low-resistance pulmonary bed and will suffer acute fatal Right Ventricular Failure in the operating room if anastomosed against fixed high Pulmonary Vascular Resistance (PVR).
    • Hemodynamic Cut-offs (ISHLT 2016): A Pulmonary Artery Systolic Pressure (PASP) of 50 mmHg or more with either a Transpulmonary Gradient (TPG = mPAP minus PCWP) of 15 mmHg or more or a PVR above 3 Wood Units mandates an acute vasodilator challenge; a PVR that stays above 5 Wood Units (or Indexed PVR above 6 Wood Units·m2) markedly raises the risk of donor RV failure (using IV Sodium Nitroprusside, Inhaled Nitric Oxide, or Milrinone).
    • Unloading Trial Before Listing: If PVR fails to fall below 3 to 5 Wood Units acutely (or drops only at the expense of systemic hypotension, SBP <85 mmHg), a 24-to-72-hour ICU trial of continuous inotropes/vasodilators/IABP or durable Left Ventricular Assist Device (LVAD) implantation for 3 to 6 months is performed to mechanically unload the left atrium and remodel the pulmonary vasculature; if PVR remains irreversibly fixed above 5 Wood Units despite LVAD unloading, isolated orthotopic heart transplantation is contraindicated (requiring heart-lung transplantation).
    • Other Relative and Absolute Contraindications:
    • Age and Obesity: Age >70 years (selected patients >70 yr may be considered via alternate-list criteria) and Class II Obesity (BMI >=35 kg/m2) (associated with poor post-transplant survival; weight loss to BMI <35 kg/m2 is recommended prior to listing).
    • Active Malignancy or Infection: Active neoplasm (other than non-melanoma skin cancer; requires oncology collaboration to define a low-recurrence remission window) or uncontrolled systemic infection.
    • Irreversible Extracardiac Organ Dysfunction: Irreversible renal dysfunction (eGFR <30 mL/min/1.73 m2) or cirrhosis is a contraindication to isolated heart transplantation, and requires Simultaneous Heart-Kidney or Heart-Liver Transplantation.
    • Severe Peripheral/Cerebrovascular Disease, Diabetes with Severe End-Organ Damage, Active Substance/Tobacco Use within 6 Months, or Psychosocial Non-Adherence.

IIIDONOR MATCHING, ALLOCATION AND ORGAN PRESERVATION

  • ABO Blood Group Compatibility: Mandatory ABO compatibility (identical or compatible blood group) in adults. (Pediatric Exception: ABO-incompatible heart transplantation is safely performed in infants under 1 to 2 years of age before isohemagglutinin antibody production matures.)
  • Predicted Heart Mass (PHM) and Weight Sizing: Donor-to-recipient body weight ratio (0.8 to 1.2; or Predicted Heart Mass [PHM] within 20 to 30 percent) is required; undersizing a female donor heart into a larger male recipient by >20 to 30% PHM is strictly avoided, especially if recipient PVR is mildly elevated.
  • Immunological HLA / PRA Screening: Panel Reactive Antibody (calculated PRA [cPRA]) and single-antigen bead (Luminex) screening identify preformed Donor-Specific Antibodies (DSA); a Virtual Crossmatch (or prospective cytotoxic/flow crossmatch plus perioperative desensitization with plasmapheresis/IVIG/rituximab/eculizumab in highly sensitized recipients with cPRA >50–80%) prevents hyperacute rejection.
  • Cold Ischemic Time vs. Ex-Vivo Normothermic Perfusion & DCD Hearts:
    • Traditional Cold Static Storage: Target cold ischemic time less than 4 hours (prolonged ischemia >4 to 6 hours sharply increases Primary Graft Dysfunction [PGD] and 1-year mortality).
    • Donation After Circulatory Death (DCD) and Ex-Vivo Perfusion (“Heart-in-a-Box”): Controlled temperature preservation (SherpaPak) and ex-vivo normothermic machine perfusion (TransMedics Organ Care System [OCS Heart] — EXPAND Trial and the randomized DCD Heart Trial, NEJM 2023) or Thoracoabdominal Normothermic Regional Perfusion (TA-NRP) allow safe transplantation of DCD hearts and extended-criteria/long-distance (>4–6 hour) donor hearts, expanding the donor pool by 20 to 30 percent with 6-month and 1-year survival equivalent to traditional brain-dead (DBD) donors.
Post-Transplant Timeline Dominant Complications Key Diagnostic / Surveillance Modality First-Line Management Strategy
Immediate (0 to 30 Days) Primary Graft Dysfunction (PGD) & Acute RV Failure; Hyperacute rejection Echocardiography + RHC hemodynamics Inotropes, inhaled NO, and early VA-ECMO for severe PGD
Early (1 Month to 1 Year) Acute Cellular Rejection (ACR — T-cell) & Antibody-Mediated Rejection (AMR — DSA/C4d); Opportunistic infections (CMV, Pneumocystis) Endomyocardial Biopsy (EMB — ISHLT Grade 0R to 3R; pAMR 0 to 3) OR non-invasive Donor-Derived Cell-Free DNA (dd-cfDNA) & GEP (AlloMap) ACR (>=2R): High-dose IV Methylprednisolone (+ ATG if hemodynamic compromise); AMR: Steroids + Plasmapheresis + IVIG + Rituximab/Bortezomib
Late (> 1 Year to 10+ Years) Cardiac Allograft Vasculopathy (CAV), Malignancy (skin cancer, PTLD), & CNI nephrotoxicity Annual Coronary Angiography + IVUS (intimal thickening >=0.5 mm), CCTA, or Quantitative Stress PET (MFR) Universal Upfront Statin (Pravastatin/Simvastatin — Class I) + switch MMF to mTOR Inhibitor (Sirolimus / Everolimus — Class IIa)

IVPOST-TRANSPLANT IMMUNOSUPPRESSION, DENERVATED PHYSIOLOGY AND COMPLICATIONS

  • Standard Maintenance Triple Immunosuppression:
    • Calcineurin Inhibitor (CNI — Backbone): Tacrolimus (preferred over Cyclosporine due to lower acute rejection rates, less hypertension/dyslipidemia, and absence of gingival hyperplasia/hirsutism; causes tremor, post-transplant diabetes, and nephrotoxicity).
    • Antimetabolite (Purine Synthesis Inhibitor): Mycophenolate Mofetil (MMF) or Enteric-Coated Mycophenolate Sodium (replaced by Proliferation Signal / mTOR Inhibitors [Everolimus or Sirolimus] after 3 to 6 months in patients who develop CAV, CNI nephrotoxicity, or post-transplant malignancy; note that mTOR inhibitors must not be started immediately post-op because they impair sternal wound healing and cause pericardial effusions).
    • Corticosteroids: Intravenous Methylprednisolone intraoperatively, followed by oral Prednisone tapered off over 6 to 12 months in rejection-free recipients.
    • Mandatory Universal Co-Medications: Statins (initiated in all recipients at 1 to 2 weeks post-transplant regardless of cholesterol levels [Class I] because randomized trials with Pravastatin and Simvastatin proved reductions in acute rejection, CAV, and 1-year mortality), plus Valganciclovir (for CMV prophylaxis) and Trimethoprim-Sulfamethoxazole (for Pneumocystis jirovecii and Toxoplasma prophylaxis).
    • Physiology and Pharmacology of the Surgically Denervated Heart (Crucial Exam Concept):
    • Loss of Efferent Vagal and Sympathetic Innervation: Because the donor heart lacks parasympathetic vagal tone, the resting sinus heart rate is elevated at 90 to 110 bpm with loss of respiratory sinus arrhythmia. During exercise, heart rate rises slowly over 5 to 10 minutes (driven purely by circulating adrenal catecholamines rather than immediate neural sympathetic discharge) and decelerates slowly during recovery.
    • Absence of Angina During Myocardial Ischemia: Because afferent cardiac sympathetic pain fibers are transected, patients with Cardiac Allograft Vasculopathy (CAV) or acute MI typically do NOT experience chest pain (angina), presenting instead with silent heart failure, dyspnea, syncope, ventricular arrhythmias, or sudden death (partial sympathetic reinnervation may occur in 30 to 40 percent after 3 to 5 years).
    • Altered Drug Responses in the Denervated Heart:
    • Atropine and Digoxin (Vagotonic Effect): Completely INEFFECTIVE for increasing or slowing the donor sinus node / AV node because the vagus nerve is disconnected from the donor heart (if the native recipient right atrial cuff remains in a biatrial anastomosis, Atropine speeds only the native P wave, not the conducted donor heart rate). Use Isoproterenol, Epinephrine, or Terbutaline/Theophylline for bradycardia.
    • Adenosine: Exhibits marked denervation supersensitivity (3- to 5-fold exaggerated effect), causing prolonged ventricular asystole; if used, start at a fraction of the normal dose (1.5 to 3 mg).
    • Cardiac Allograft Vasculopathy (CAV — The Leading Cause of Late Graft Loss and Death After Year 1): An immunologically mediated pan-arteritis characterized by diffuse, concentric fibrous intimal hyperplasia along the entire length of both epicardial and intramyocardial coronary vessels (unlike focal, eccentric lipid-rich atherosclerotic plaques, and typically sparing the native calcium). Because percutaneous stenting is only palliative, prevention relies on universal Statins (Class I), Diltiazem/Vitamins C & E, and conversion from MMF to Sirolimus or Everolimus (mTOR inhibitors — Class IIa), with re-transplantation reserved for severe ISHLT Grade 3 CAV with graft dysfunction.
    • ISHLT Survival Outcomes: Contemporary adult 1-year survival approaches 90 to 91 percent, overall median survival is 12.5 to 13 years, and conditional median survival for recipients who survive the first post-operative year exceeds 15 years.

Key references

  • Mehra MR, Canter CE, Hannan MM, et al. (ISHLT Consensus): The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update, Journal of Heart and Lung Transplantation, 2016.
  • Velleca A, Shullo MA, Dhital K, et al.: The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients, Journal of Heart and Lung Transplantation, 2023.
  • Schroder JN, Patel CB, DeVore AD, et al. (DCD Heart Trial Investigators): Transplantation Outcomes with Donor Hearts after Circulatory Death, New England Journal of Medicine, 2023.
  • McDonagh TA, Metra M, Adamo M, et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal, 2021.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.